Collegium PharmaceuticalCOLL
Recorded

Collegium Pharmaceutical Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Dennis DingBiotech and Spec Pharma Analyst

Hi, good morning. Welcome to the Jefferies London Healthcare Conference. My name is Dennis Ding, biotech and spec pharma analyst here at Jefferies. I have the wonderful pleasure of having Collegium Pharmaceutical here. I have the CFO, Colleen Tupper, as well as Ian Karp, IR. Maybe just first off, give us a big picture overview around Collegium, some of the progress you guys have made this year, and maybe talk about your outlook into 2027.

Colleen TupperCFO

Great. Thanks, Dennis, and thanks for having us. Collegium is a dynamic biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions. There are three main components to our business model. That's we identify differentiated medicines that address meaningful patient needs, we apply focused commercial execution to accelerate growth, and we create value through strategic acquisition and then seamless integration. To date, we've built the industry's leading organization to responsibly support the management of severe chronic pain, and most recently, we've expanded into ADHD. Can we go one more up? While our pain portfolio remains an important foundation of the company, ADHD now represents the fastest-growing segment of our business and generates approximately 36% of total revenues. Our first ADHD medicine, Jornay PM, grew 48% in 2025, and we expect about 31% growth this year, with revenues between $190 million and $200 million.

Colleen TupperCFO

In May of this past year, we acquired our second ADHD medicine, Azstarys, a highly complementary offering to Jornay, and it's expected to deliver between $65 million and $75 million in its first partial year, with further growth expected in 2027 and beyond. In our most recent quarter, our first full quarter of owning Azstarys, we have seen prescription volumes return to growth following an overall decline in 2025. Our total diversified portfolio of medicines is expected to generate between $825 million to $855 million of revenue this year, approximately 8% growth year-over-year. Importantly, our business continues to be highly profitable, with an adjusted EBITDA margin of over 50%, well above typical norms in specialty pharma space.

Colleen TupperCFO

Looking ahead, we remain focused on driving growth in ADHD and maximizing the performance of our pain portfolio, and deploying capital in a thoughtful manner through business development, debt reduction, and opportunistically buying shares back.

Dennis DingBiotech and Spec Pharma Analyst

Perfect. ADHD has obviously been a big growth driver for you, and you guys have around 190 reps on the ground. Do you think that is optimized now that you have integrated Azstarys into the business? Now that you have two products, does that actually open up more opportunities in these doctors' offices for you guys?

Colleen TupperCFO

Yeah, we do believe our commercial organization is the right size and have no current plans to increase the number of our sales reps. We have an efficient single sales force selling both products, and they are focused on activating healthcare providers and increasing the depth of prescribing. Based on our growth opportunities in ADHD, we have increased our sales force size two times in the past two years, first going from 125 reps up to 180, and then most recently, following the acquisition of Azstarys, increasing to about 190 territories. We are targeting about 27,000 healthcare providers for both Azstarys and Jornay, and we have heard from physicians in the early days of having both products available to them that they really find it to be an efficient call, and they do like hearing about both products in one call.

Colleen TupperCFO

Our targeted patient and caregiver outreach, particularly through social media platforms, has successfully increased awareness and trial for Jornay PM and represents an additional opportunity to support growth across both brands.

Dennis DingBiotech and Spec Pharma Analyst

Can you explain the different types of patients that would go on to Jornay versus Azstarys, and is there a major distinction between those types of patients?

Ian KarpHead of Investor Relations

Yeah, sure. Maybe I will take that one. Jornay and Azstarys really are differentiated and complementary medicines, so it is important to keep that context in mind. They really do target different types of patients, which allow us to really help a broad set of patients. Both medicines can last all day. They offer a smooth offset, which is particularly important as it can help avoid what is sometimes known as a treatment crash, which can be seen with other ADHD medicines. But the main differences between the two, really around the timing of their symptom control. Jornay PM is the first and only stimulant that is delivered at night, okay? So you take it typically before bedtime, and it delivers symptom control upon the patient awakening. This can be particularly important for patients who have really problematic ADHD symptoms first thing in the morning.

Ian KarpHead of Investor Relations

For a child or adolescent, that could mean a difficult time getting up in the morning, getting to school, so taking your Jornay at night and having it work immediately upon awakening can really be beneficial to those patients. Azstarys works a bit differently. It is the only medicine that has both a fast-acting and long-acting ADHD medicine in one capsule. That is typically preferred by the patient who has a bit more variability in their schedule, so they may not necessarily be getting up at the exact same time every day. But when they do need their symptom control, they need it to begin working as quickly as possible, and oftentimes they need that lasting throughout the day. That is generally where Azstarys is positioned.

Ian KarpHead of Investor Relations

Both have, I would say, very strong perceptions by healthcare providers, and part of that has been the marketing efforts that we have undertaken since acquiring Jornay two years ago, and we are just really getting going now with Azstarys, as it came into our portfolio just this past May.

Dennis DingBiotech and Spec Pharma Analyst

How do you guys think about balancing promotion between these two products with doctors?

Colleen TupperCFO

It can be sometimes physician-dependent. There certainly are physicians that we can see through the data have prescribed more of Azstarys and/or more of Jornay. As each rep is planning their individual call to that physician, they will tailor it to its needs based on their prescribing habits. Also, if there are physicians that have not prescribed one or the other, then they are making sure that they are well-informed about that additional product.

Dennis DingBiotech and Spec Pharma Analyst

Okay. For Jornay specifically, you have had the asset for several years now.

Dennis DingBiotech and Spec Pharma Analyst

You guys have seen a lot of revenue growth. I would say part of that growth was driven by pricing, right? Are we at a generally stable gross-to-net today, or could that further be optimized potentially in 2027 or 2028?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day